Intranasal vaccine for use against disease caused by enterotoxigenic Escherichia coli
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 23, 2010
Grant Date -
Jan 29, 2009
app pub date -
Oct 26, 2006
filing date -
Nov 8, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The disclosure relates to an intranasal peptide vaccine for use against infection caused by enterotoxigenic Escherichia coli (ETEC), containing a common linear protein epitope known as CLE which is recognized by sera of patients infected with the bacteria and which is associated with a mucosal adjuvant comprising cholera toxin subunit B, known as CTB. The disclosure relates to a peptide containing twenty amino acids, which is located in the linear sequence of the CFA/I fimbria of enterotoxigenic Escherichia coli.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully